

Zydus receives approval for Mycophenolate Mofetil tablets and capsules

Ahmedabad, 5 May 2009

Zydus Cadila has received an approval from the USFDA to market Mycophenolate Mofetil Tablets, 500 mg and Mycophenolate Mofetil Capsules, 250 mg which fall in the immuno-suppressant segment.

The estimated sales in 2008 as per NDC for Mycophenolate Mofetil Tablets was USD 648 million and for Mycophenolate Mofetil Capsules was USD 316 million.

The group now has 46 approvals and has so far filed 92 ANDAs since the commencement of filing process in FY 2003-04.
